Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus

Table 1

Comparison between responders ( = 63) and nonresponders ( = 49) in patient demographics and medications prescribed alongside exenatide. Results are presented as the mean ± SD for continuous variables and as the number (plus percentage) for categorical variables.

Variable	Group		value
	Responders	Nonresponders
Gender male (% male)	36 (57)	28 (57)	1.00
Age	59 ± 11	61 ± 10	0.16
Duration of T2DM in years	14 ± 6.06	14.9 ± 5.83	0.40
Prescribed exenatide only (%)	5 (7.94)	2 (4.08)	0.46
Prescribed exenatide with OHAs only (%)	45 (71.4)	27 (55.1)	0.11
Prescribed exenatide with insulin only (%)	2 (3.17)	10 (20.4)	0.0047
Prescribed exenatide with OHAs and insulin (%)	11 (17.5)	10 (20.4)	0.88

OHA: oral antihyperglycaemic agent; T2DM: type 2 diabetes mellitus.